↑ 薬物リストへ　← 戻る

See below for fcx-007 description)    (DrugBank: -)

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
36表皮水疱症1

36. 表皮水疱症　［臨床試験数：147，薬物数：170（DrugBank：40），標的遺伝子数：32，標的パスウェイ数：113］
Searched query = "Epidermolysis bullosa", "EBS", "JEB", "DDEB", "RDEB", "Kindler syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 147 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04213261
(ClinicalTrials.gov)		June 9, 20202/12/2019A Study of FCX-007 for Recessive Dystrophic Epidermolysis BullosaA Pivotal Phase 3 Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis BullosaRecessive Dystrophic Epidermolysis BullosaBiological: FCX-007 (debcoemagene autoficel; see below for FCX-007 description)Fibrocell Technologies, Inc.NULLRecruiting2 YearsN/AAll24Phase 3United States